{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T18:32:44Z","timestamp":1758220364127,"version":"3.44.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA116339"],"award-info":[{"award-number":["T32 CA116339"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["MRSG-13-157-01-CPPB"],"award-info":[{"award-number":["MRSG-13-157-01-CPPB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Adjuvant endocrine therapy (ET) is recommended to women with hormone receptor-positive (HR\u2009+) breast cancer for 5\u201310\u00a0years to reduce recurrence risk and mortality, but adhering to ET for this full period is challenging due to the physical and psychosocial effects of treatment. We sought to understand how participation in a patient-centered counseling intervention affected anxiety and depression, recurrence worry, and treatment related symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a single-arm pilot study over a 12-month period, consisting of five counselor-led motivational interviewing (MI) counseling sessions. Eligible participants were over 18\u00a0years old, English speaking, and had stage I-III HR\u2009+\u2009breast cancer. Survey data collected at baseline and 12\u00a0months assessed anxiety and depression, and cancer recurrence worry. Endocrine symptoms were assessed at the 12-month time point, reported descriptively, and age-stratified to examine if symptom burden and age were related.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 42 women who initiated the intervention, 35 completed the baseline and 12-month surveys. Most participants were over 50 (63%), non-Black and non-Hispanic (63%; 97%). Overall patient-reported anxiety and depression decreased from baseline to 12\u00a0months, though only the change in anxiety was statistically significant, while cancer worry increased slightly. The most reported endocrine symptoms were hot flashes, night sweats, vaginal dryness, disinterest in sex, and joint pain; endocrine symptoms did not vary by age.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study shows early promise in the efficacy of MI to improve anxiety, depression, recurrence worry, and treatment-related endocrine symptoms.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09760-8","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T22:35:09Z","timestamp":1755902109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of motivational interviewing on psychosocial and symptom outcomes during breast cancer endocrine therapy"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-7736","authenticated-orcid":false,"given":"Charlotte","family":"Ellis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6903-0177","authenticated-orcid":false,"given":"Katherine","family":"Reeder-Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-6285","authenticated-orcid":false,"given":"Sarah","family":"Drier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-8535","authenticated-orcid":false,"given":"Austin R.","family":"Waters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer C.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"9472","key":"9760_CR1","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet Lond Engl 365(9472):1687\u20131717. https:\/\/doi.org\/10.1016\/S0140-6736(05)66544-0","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"9760_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209\u2013219.https:\/\/doi.org\/10.1056\/NEJMoa1604700","journal-title":"N Engl J Med"},{"issue":"17","key":"9760_CR3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG.MA 17. J Natl Cancer Inst 97(17):1262\u20131271. https:\/\/doi.org\/10.1093\/jnci\/dji250","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"9760_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1200\/JOP.2012.000543","volume":"8","author":"EJ Aiello Bowles","year":"2012","unstructured":"Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer | JCO Oncology Practice. Am Soc Clin Oncol 8(6):149\u2013157. https:\/\/doi.org\/10.1200\/JOP.2012.000543","journal-title":"Am Soc Clin Oncol"},{"issue":"7","key":"9760_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ctrv.2008.04.001","volume":"34","author":"C Buijs","year":"2008","unstructured":"Buijs C, de Vries EGE, Mourits MJE, Willemse PHB (2008) The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev 34(7):640\u2013655. https:\/\/doi.org\/10.1016\/j.ctrv.2008.04.001","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"9760_CR6","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1200\/JCO.2001.19.2.322","volume":"19","author":"S Demissie","year":"2001","unstructured":"Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol Off J Am Soc Clin Oncol 19(2):322\u2013328. https:\/\/doi.org\/10.1200\/JCO.2001.19.2.322","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"16","key":"9760_CR7","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1200\/JCO.2004.11.064","volume":"22","author":"AK Fink","year":"2004","unstructured":"Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor\u2013positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 22(16):3309\u20133315. https:\/\/doi.org\/10.1200\/JCO.2004.11.064","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"9760_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10549-006-9193-0","volume":"99","author":"TL Lash","year":"2006","unstructured":"Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215\u2013220. https:\/\/doi.org\/10.1007\/s10549-006-9193-0","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"9760_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pec.2004.10.005","volume":"59","author":"EA Grunfeld","year":"2005","unstructured":"Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 59(1):97\u2013102. https:\/\/doi.org\/10.1016\/j.pec.2004.10.005","journal-title":"Patient Educ Couns"},{"issue":"2","key":"9760_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10549-016-3871-3","volume":"158","author":"EE Bright","year":"2016","unstructured":"Bright EE, Petrie KJ, Partridge AH, Stanton AL (2016) Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Breast Cancer Res Treat 158(2):243\u2013251. https:\/\/doi.org\/10.1007\/s10549-016-3871-3","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"9760_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1017\/S135246580001643X","volume":"23","author":"S Rollnick","year":"1995","unstructured":"Rollnick S, Miller WR (1995) What is motivational interviewing? Behav Cogn Psychother 23(4):325\u2013334. https:\/\/doi.org\/10.1017\/S135246580001643X","journal-title":"Behav Cogn Psychother"},{"issue":"7","key":"9760_CR12","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3390\/cancers15071973","volume":"15","author":"SB Wheeler","year":"2023","unstructured":"Wheeler SB, Spencer J, Drier SW, Fray N, Reeder-Hayes KE (2023) Motivational interviewing counseling to increase endocrine therapy adherence in diverse patients. Cancers 15(7):1973. https:\/\/doi.org\/10.3390\/cancers15071973","journal-title":"Cancers"},{"key":"9760_CR13","doi-asserted-by":"publisher","unstructured":"Fisher WA, Fisher JD, Harman J (2009) The information-motivation-behavioral skills model: a general social psychological approach to understanding and promoting health behavior. In: Social Psychological Foundations of Health and Illness pp 82\u2013106. https:\/\/doi.org\/10.1002\/9780470753552.ch4","DOI":"10.1002\/9780470753552.ch4"},{"key":"9760_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/CMAR.S64165","volume":"7","author":"CR Rouleau","year":"2015","unstructured":"Rouleau CR, Garland SN, Carlson LE (2015) The impact of mindfulness-based interventions on symptom burden, positive psychological outcomes, and biomarkers in cancer patients. Cancer Manag Res 7:121\u2013131. https:\/\/doi.org\/10.2147\/CMAR.S64165","journal-title":"Cancer Manag Res"},{"issue":"4","key":"9760_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/08870449808407422","volume":"13","author":"A Bandura","year":"1998","unstructured":"Bandura A (1998) Health promotion from the perspective of social cognitive theory. Psychol Health 13(4):623\u2013649. https:\/\/doi.org\/10.1080\/08870449808407422","journal-title":"Psychol Health"},{"issue":"10","key":"9760_CR16","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1007\/s00520-014-2269-1","volume":"22","author":"RA Shelby","year":"2014","unstructured":"Shelby RA, Edmond SN, Wren AA et al (2014) Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy. Support Care Cancer 22(10):2851\u20132859. https:\/\/doi.org\/10.1007\/s00520-014-2269-1","journal-title":"Support Care Cancer"},{"issue":"6","key":"9760_CR17","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/07347332.2013.835023","volume":"31","author":"SN Edmond","year":"2013","unstructured":"Edmond SN, Shelby RA, Kimmick GG, Marcom PK, Peppercorn JM, Keefe FJ (2013) Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment. J Psychosoc Oncol 31(6):698\u2013711. https:\/\/doi.org\/10.1080\/07347332.2013.835023","journal-title":"J Psychosoc Oncol"},{"issue":"5","key":"9760_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/01.mlr.0000257193.10760.7f","volume":"45","author":"KL Kahn","year":"2007","unstructured":"Kahn KL, Schneider EC, Malin JL, Adams JL, Epstein AM (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431\u2013439. https:\/\/doi.org\/10.1097\/01.mlr.0000257193.10760.7f","journal-title":"Med Care"},{"issue":"1","key":"9760_CR19","doi-asserted-by":"publisher","first-page":"E44","DOI":"10.1097\/NCC.0b013e3182813a17","volume":"37","author":"JAE Custers","year":"2014","unstructured":"Custers JAE, van den Berg SW, van Laarhoven HWM, Bleiker EMA, Gielissen MFM, Prins JB (2014) The Cancer Worry Scale: detecting fear of recurrence in breast cancer survivors. Cancer Nurs 37(1):E44. https:\/\/doi.org\/10.1097\/NCC.0b013e3182813a17","journal-title":"Cancer Nurs"},{"issue":"7","key":"9760_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.pec.2016.02.003","volume":"99","author":"JC Spencer","year":"2016","unstructured":"Spencer JC, Wheeler SB (2016) A systematic review of Motivational Interviewing interventions in cancer patients and survivors. Patient Educ Couns 99(7):1099\u20131105. https:\/\/doi.org\/10.1016\/j.pec.2016.02.003","journal-title":"Patient Educ Couns"},{"issue":"1","key":"9760_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/01.qai.0000219771.97303.0a","volume":"42","author":"CE Golin","year":"2006","unstructured":"Golin CE, Earp J, Tien HC, Stewart P, Porter C, Howie L (2006) A 2-arm, randomized, controlled trial of a motivational interviewing\u2013based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J Acquir Immune Defic Syndr 1999 42(1):42\u201351. https:\/\/doi.org\/10.1097\/01.qai.0000219771.97303.0a","journal-title":"J Acquir Immune Defic Syndr 1999"},{"issue":"4","key":"9760_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/108729104323038900","volume":"18","author":"MS Adamian","year":"2004","unstructured":"Adamian MS, Golin CE, Shain LS, DeVellis B (2004) Brief motivational interviewing to improve adherence to antiretroviral therapy: development and qualitative pilot assessment of an intervention. AIDS Patient Care STDs 18(4):229\u2013238. https:\/\/doi.org\/10.1089\/108729104323038900","journal-title":"AIDS Patient Care STDs"},{"issue":"1","key":"9760_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pec.2005.06.003","volume":"62","author":"AD Thrasher","year":"2006","unstructured":"Thrasher AD, Golin CE, Earp JAL, Tien H, Porter C, Howie L (2006) Motivational interviewing to support antiretroviral therapy adherence: the role of quality counseling. Patient Educ Couns 62(1):64\u201371. https:\/\/doi.org\/10.1016\/j.pec.2005.06.003","journal-title":"Patient Educ Couns"},{"key":"9760_CR24","unstructured":"PROMIS. https:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis. Accessed November 14, 2023."},{"key":"9760_CR25","unstructured":"Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS\u00ae): Depression, Anxiety, and Anger - PMC. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3153635\/. Accessed April 1, 2024."},{"key":"9760_CR26","unstructured":"Validation of the depression item bank from the Patient-Reported Outcomes Measurement Information System (PROMIS\u00ae) in a three-month observational study - PMC. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4096965\/. Accessed April 1, 2024."},{"issue":"10","key":"9760_CR27","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s11136-021-02925-y","volume":"30","author":"CB Terwee","year":"2021","unstructured":"Terwee CB, Peipert JD, Chapman R et al (2021) Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual Life Res 30(10):2729\u20132754. https:\/\/doi.org\/10.1007\/s11136-021-02925-y","journal-title":"Qual Life Res"},{"issue":"6","key":"9760_CR28","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1634\/theoncologist.2015-0007","volume":"20","author":"SM Rosenberg","year":"2015","unstructured":"Rosenberg SM, Stanton AL, Petrie KJ, Partridge AH (2015) Symptoms and symptom attribution among women on endocrine therapy for breast cancer. Oncologist 20(6):598\u2013604. https:\/\/doi.org\/10.1634\/theoncologist.2015-0007","journal-title":"Oncologist"},{"issue":"3","key":"9760_CR29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10549-011-1893-4","volume":"132","author":"W Lorizio","year":"2012","unstructured":"Lorizio W, Wu AHB, Beattie MS et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 132(3):1107\u20131118. https:\/\/doi.org\/10.1007\/s10549-011-1893-4","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"9760_CR30","doi-asserted-by":"publisher","first-page":"CD003370","DOI":"10.1002\/14651858.CD003370.pub3","volume":"2009","author":"L Gibson","year":"2009","unstructured":"Gibson L, Lawrence D, Dawson C, Bliss J (2009) Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009(4):CD003370. https:\/\/doi.org\/10.1002\/14651858.CD003370.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"9760_CR31","unstructured":"Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment - PMC. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4710358\/. Accessed March 29, 2024."},{"issue":"6","key":"9760_CR32","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1037\/a0030186","volume":"32","author":"S Lebel","year":"2013","unstructured":"Lebel S, Beattie S, Ar\u00e8s I, Bielajew C (2013) Young and worried: age and fear of recurrence in breast cancer survivors. Health Psychol 32(6):695\u2013705. https:\/\/doi.org\/10.1037\/a0030186","journal-title":"Health Psychol"},{"key":"9760_CR33","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1200\/EDBK_320595","volume":"41","author":"I Vaz-Luis","year":"2021","unstructured":"Vaz-Luis I, Francis PA, Di Meglio A, Stearns V (2021) Challenges in adjuvant therapy for premenopausal women diagnosed with luminal breast cancers. Am Soc Clin Oncol Educ Book 41:e47\u2013e61. https:\/\/doi.org\/10.1200\/EDBK_320595","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"9760_CR34","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/curroncol30020112","volume":"30","author":"R Rosso","year":"2023","unstructured":"Rosso R, D\u2019Alonzo M, Bounous VE et al (2023) Adherence to adjuvant endocrine therapy in breast cancer patients. Curr Oncol 30(2):1461\u20131472. https:\/\/doi.org\/10.3390\/curroncol30020112","journal-title":"Curr Oncol"},{"issue":"4","key":"9760_CR35","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.amjsurg.2006.06.018","volume":"192","author":"JR Garreau","year":"2006","unstructured":"Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N (2006) Side effects of aromatase inhibitors versus tamoxifen: the patients\u2019 perspective. Am J Surg 192(4):496\u2013498. https:\/\/doi.org\/10.1016\/j.amjsurg.2006.06.018","journal-title":"Am J Surg"},{"issue":"3","key":"9760_CR36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10549-022-06810-1","volume":"197","author":"SM Rosenberg","year":"2023","unstructured":"Rosenberg SM, Zheng Y, Gelber S et al (2023) Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer. Breast Cancer Res Treat 197(3):547\u2013558. https:\/\/doi.org\/10.1007\/s10549-022-06810-1","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"9760_CR37","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1245\/s10434-018-6616-1","volume":"25","author":"SE Tevis","year":"2018","unstructured":"Tevis SE, James TA, Kuerer HM et al (2018) Patient-reported outcomes for breast cancer. Ann Surg Oncol 25(10):2839\u20132845. https:\/\/doi.org\/10.1245\/s10434-018-6616-1","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"9760_CR38","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jval.2019.04.1927","volume":"22","author":"LSE van Egdom","year":"2019","unstructured":"van Egdom LSE, Oemrawsingh A, Verweij LM et al (2019) Implementing patient-reported outcome measures in clinical breast cancer care: a systematic review. Value Health 22(10):1197\u20131226. https:\/\/doi.org\/10.1016\/j.jval.2019.04.1927","journal-title":"Value Health"},{"issue":"6","key":"9760_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","volume":"34","author":"E Basch","year":"2016","unstructured":"Basch E, Deal AM, Kris MG et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557\u2013565. https:\/\/doi.org\/10.1200\/JCO.2015.63.0830","journal-title":"J Clin Oncol"},{"issue":"3","key":"9760_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10549-018-5012-7","volume":"173","author":"SP Heiney","year":"2019","unstructured":"Heiney SP, Parker PD, Felder TM, Adams SA, Omofuma OO, Hulett JM (2019) A systematic review of interventions to improve adherence to endocrine therapy. Breast Cancer Res Treat 173(3):499\u2013510. https:\/\/doi.org\/10.1007\/s10549-018-5012-7","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"9760_CR41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11764-017-0674-4","volume":"12","author":"E Ekinci","year":"2018","unstructured":"Ekinci E, Nathoo S, Korattyil T et al (2018) Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Cancer Surviv 12(3):348\u2013356. https:\/\/doi.org\/10.1007\/s11764-017-0674-4","journal-title":"J Cancer Surviv"},{"issue":"1","key":"9760_CR42","doi-asserted-by":"publisher","first-page":"107327481988328","DOI":"10.1177\/1073274819883287","volume":"26","author":"JL Krok-Schoen","year":"2019","unstructured":"Krok-Schoen JL, Naughton MJ, Young GS et al (2019) Increasing adherence to adjuvant hormone therapy among patients with breast cancer: a smart phone app-based pilot study. Cancer Control J Moffitt Cancer Cent 26(1):1073274819883287. https:\/\/doi.org\/10.1177\/1073274819883287","journal-title":"Cancer Control J Moffitt Cancer Cent"},{"issue":"19","key":"9760_CR43","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1002\/cncr.34409","volume":"128","author":"JM Jacobs","year":"2022","unstructured":"Jacobs JM, Post K, Massad K et al (2022) A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: a randomized controlled trial. Cancer 128(19):3541\u20133551. https:\/\/doi.org\/10.1002\/cncr.34409","journal-title":"Cancer"},{"issue":"13","key":"9760_CR44","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1200\/JCO.2011.36.8597","volume":"30","author":"BJ Caan","year":"2012","unstructured":"Caan BJ, Emond JA, Su HI et al (2012) Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol 30(13):1492\u20131497. https:\/\/doi.org\/10.1200\/JCO.2011.36.8597","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"9760_CR45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10549-010-0802-6","volume":"124","author":"HI Su","year":"2010","unstructured":"Su HI, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ (2010) Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 124(1):205\u2013211. https:\/\/doi.org\/10.1007\/s10549-010-0802-6","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"9760_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(11)70364-3","volume":"13","author":"E Mann","year":"2012","unstructured":"Mann E, Smith MJ, Hellier J et al (2012) Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol 13(3):309\u2013318. https:\/\/doi.org\/10.1016\/S1470-2045(11)70364-3","journal-title":"Lancet Oncol"},{"issue":"31","key":"9760_CR47","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1200\/JCO.2015.60.9412","volume":"33","author":"JJ Mao","year":"2015","unstructured":"Mao JJ, Bowman MA, Xie SX, Bruner D, DeMichele A, Farrar JT (2015) Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial. J Clin Oncol Off J Am Soc Clin Oncol 33(31):3615\u20133620. https:\/\/doi.org\/10.1200\/JCO.2015.60.9412","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"9760_CR48","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10549-010-1283-3","volume":"135","author":"A Liljegren","year":"2012","unstructured":"Liljegren A, Gunnarsson P, Landgren BM, Rob\u00e9us N, Johansson H, Rotstein S (2012) Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant tamoxifen: a randomized controlled trial. Breast Cancer Res Treat 135(3):791\u2013798. https:\/\/doi.org\/10.1007\/s10549-010-1283-3","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"9760_CR49","doi-asserted-by":"publisher","first-page":"e2241720","DOI":"10.1001\/jamanetworkopen.2022.41720","volume":"5","author":"DL Hershman","year":"2022","unstructured":"Hershman DL, Unger JM, Greenlee H et al (2022) Comparison of acupuncture vs sham acupuncture or waiting list control in the treatment of aromatase inhibitor\u2013related joint pain: a randomized clinical trial. JAMA Netw Open 5(11). https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.41720","journal-title":"JAMA Netw Open"},{"issue":"7","key":"9760_CR50","doi-asserted-by":"publisher","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","volume":"22","author":"MA Franzoi","year":"2021","unstructured":"Franzoi MA, Agostinetto E, Perachino M et al (2021) Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol 22(7):e303\u2013e313. https:\/\/doi.org\/10.1016\/S1470-2045(20)30666-5","journal-title":"Lancet Oncol"},{"issue":"8","key":"9760_CR51","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.3390\/ijerph17082950","volume":"17","author":"CWH Chan","year":"2020","unstructured":"Chan CWH, Tai D, Kwong S, Chow KM, Chan DNS, Law BMH (2020) The effects of pharmacological and non-pharmacological interventions on symptom management and quality of life among breast cancer survivors undergoing adjuvant endocrine therapy: a systematic review. Int J Environ Res Public Health 17(8):2950. https:\/\/doi.org\/10.3390\/ijerph17082950","journal-title":"Int J Environ Res Public Health"},{"key":"9760_CR52","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/s13063-023-07672-8","volume":"24","author":"J Ivory","year":"2023","unstructured":"Ivory J, Wheeler SB, Drier S et al (2023) Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): the GETSET protocol. Trials 24:664. https:\/\/doi.org\/10.1186\/s13063-023-07672-8","journal-title":"Trials"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09760-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09760-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09760-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T02:58:05Z","timestamp":1758164285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09760-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["9760"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09760-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All research was conducted in accordance with the Declaration of Helsinki. Study activities were approved by the University of North Carolina\u2019s Institutional Review Board (IRB #13\u20130736) and informed consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"805"}}